Anavex Life Sciences Corp (AVXL)

[end2war]

Muted response of PPS to these extremely positive results is due to a misunderstanding about the reasons for the change of the endpoint measurements. Missling explained that, for this PH3 study, this approached to the endpoints was based on FDA advice about what would be required, and it was prespecified for this study. According to Missling, they met a much more difficult endpoint standard with this required approach, and it was comparable or better than in the prior reported Study.

When the market figures it out, I believe the PPS will reflect the excellent progress, and how much this supports AVXL's other studies using the S1R receptors. Please do your own research and DD and don't rely on Posters, but I think this is a solid buy from here and they have essentially shown proof of concept and very good data in an extremely hard population to treat, getting clinical benefits of signficant size.